Testosterone Replacement Therapy in Relation With Cardiovascular Disease in Cisgender Women and Transgender People
Main finding · Composite CVD, cisgender womenResult — go to the resultHazard ratio 1.24 95% CI 1.15–1.34Authors' conclusion
Use of TTh increased the risk of CVD, CAD, and stroke among cisgender women but not among transgender people. TTh is becoming more widely accepted in women, and it is the main medical treatment for transgender males. Therefore, use of TTh should be further investigated for the prevention of CVD.
Study context
- Population
- Cisgender women (25,796) and transgender people (1580), ≥30 years old, Optum's Clinformatics Data Mart Database (2007–2021)25,796 cisgender women, 1580 transgender
- Exposure
- TTh users vs nonusers
- Outcome
- Incident composite CVD:
- CAD
- Congestive HF
- Stroke
- MI
Methodological detailsclaims database (Optum's deidentified Clinformatics Data Mart Database, 2007-2021), multivariable adjusted Cox proportional hazards models
- Claims database (Optum's deidentified Clinformatics Data Mart Database, 2007-2021)
- Multivariable adjusted Cox proportional hazards models
Main finding
Composite CVD, cisgender women
Hazard ratio
1.24
95% CI 1.15–1.34
TThvs Nonusers
HR 1.24 (95% CI 1.15–1.34)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| CAD, cisgender women | 1.26 (1.14–1.39) | |
| Stroke, cisgender women | 1.29 (1.14–1.45) | |
| 0.512Hazard ratio (log scale) |
Age-stratified cardiovascular disease (CVD), CAD and stroke, cisgender women
- Stratification by age group showed similar effects of TTh on CVD, CAD, and stroke
Original publication
Testosterone Replacement Therapy in Relation With Cardiovascular Disease in Cisgender Women and Transgender People. J Clin Endocrinol Metab. Published 1 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →